Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kimberly R. Warren"'
Autor:
Kimberly R. Warren
Publikováno v:
Reimagining Internationalization and International Initiatives at Historically Black Colleges and Universities ISBN: 9783030964894
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f3b16e7071bb4804e2bcbc7500c81f3
https://doi.org/10.1007/978-3-030-96490-0_8
https://doi.org/10.1007/978-3-030-96490-0_8
Autor:
Charlene Chester, Deanna L. Kelly, Kimberly R. Warren, Robert P. McMahon, Shuo Chen, Fang Liu, Heidi J. Wehring
Publikováno v:
Physiology & Behavior. 189:86-91
Overweight and obesity in schizophrenia are prevalent, affecting half to three-quarters of people with schizophrenia. Hyperphagia and increased meal size have also been implicated as significant contributors to the weight gain problem. Oxytocin has s
Autor:
Teodor T. Postolache, Kimberly R. Warren, Deanna L. Kelly, Maureen E. Groer, Mark A. Reynolds, Omar Pinjari
Publikováno v:
Periodontology 2000
An extensive body of experimental and clinical evidence documents the negative impact of chronic psychological stress and depression on the immune system and health. Chronic stress and depression can result in general dysregulation of the immune syst
Autor:
Stephanie Feldman, Robert P. McMahon, Joo-Cheol Shim, Heidi J. Wehring, Raymond C. Love, Kimberly R. Warren, Maju Mathew Koola, Deanna L. Kelly, Fang Liu, Kristen M. Mackowick
Publikováno v:
Journal of Psychiatric Research. 46:987-993
The impact of co-morbid substance use on mortality is not well studied in psychotic disorders. The objective of this study was to examine the impact of substance use on mortality in people with psychotic disorders and alcohol and/or drug use. We exam
Autor:
Kimberly R. Warren, Heidi J. Wehring, Robert R. Conley, Joo-Cheol Shim, Deanna L. Kelly, Robert P. McMahon, Fang Liu, Raymond C. Love
Publikováno v:
The Journal of Clinical Psychiatry. 71:304-311
BACKGROUND Cardiovascular disease (CVD) mortality in schizophrenia is more frequent than in the general population. Whether second-generation antipsychotics (SGAs) increase risk of CVD morbidity and mortality has yet to be determined. METHOD We condu
Autor:
Jared Linthicum, Mary Patricia Ball, Robert W. Buchanan, Stephanie Feldman, Robert P. McMahon, Robert R. Conley, Kimberly R. Warren, Marilyn A. Huestis, Deanna L. Kelly, David A. Gorelick, Fang Liu
Publikováno v:
Journal of Clinical Psychopharmacology. 33:118-120
Autor:
Stephanie Feldman, Kimberly R. Warren, Deanna L. Kelly, Robert J. McMahon, M.P. Ball, Robert Buchanan
Publikováno v:
Clinical schizophreniarelated psychoses. 5(1)
In recent years, several pharmacological and psychosocial interventions have examined ways to prevent or treat weight gain in people receiving second-generation antipsychotics. While there has been some success, in general, results have not been comp
Autor:
Maju Mathew Koola, David A. Gorelick, Kimberly R. Warren, Stephanie Feldman, Marilyn A. Huestis, Heidi J. Wehring, Robert P. McMahon, Fang Liu, Deanna L. Kelly, Jared Linthicum
Publikováno v:
Schizophrenia Research. 152:315-316
People with schizophrenia who have current substance use disorder (SUD) are generally excluded from clinical trials for the following reasons: safety/side effect risk, concern about adherence to the study protocol (Kreyenbuhl et al., 2011) and avoida
Autor:
David A. Gorelick, Douglas L. Boggs, Heidi J. Wehring, M. Patricia Ball, Jared Linthicum, Robert W. Buchanan, Marilyn A. Huestis, Robert R. Conley, Stephen J. Heishman, Stephanie Feldman, Kimberly R. Warren, Fang Liu, Robert P. McMahon, Deanna L. Kelly
Publikováno v:
Journal of clinical psychopharmacology. 31(1)
Weight gain is a major adverse effect of several second-generation antipsychotic medications. Rimonabant is a cannabinoid-1 receptor antagonist that promotes weight loss in the general population. We conducted a 16-week, double-blind, placebo-control
Autor:
Fang Liu, Kimberly R. Warren, Robert P. McMahon, M. Patricia Ball, Stephanie Feldman, Deanna L. Kelly
People with schizophrenia have a higher prevalence of obesity than the general population. Many people with this illness struggle with weight gain, due, in part, to medications and other factors that act as obstacles to exercise and healthy eating. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c5cf52d07804d7c12e552f558de419a
https://europepmc.org/articles/PMC3742087/
https://europepmc.org/articles/PMC3742087/